Professor Mark Viant, Executive Director
Professor Mark Viant’s expertise lies in the field of metabolomics. His research spans from method development in analytical chemistry and bioinformatics through to the application of metabolomics to medical research and toxicology. Professor Viant's profile here.
Dr Warwick Dunn, Director of Mass Spectrometry
Dr Warwick (Rick) Dunn’s research focuses on developing innovative chromatography, mass spectrometry and computational resources and their application in the study of the complex role of metabolites in human ageing and diseases. Dr Dunn's profile here.
Dr Giovanny Rodriguez Blanco
Dr Rodriguez Blanco originates from Colombia where he obtained a BSc in Chemistry and a MSc in Physical Chemistry. In 2015 he was awarded his PhD in the identification of novel biomarkers for prostate cancer using mass spectrometry-based techniques at Erasmus MC, Rotterdam under the supervision od Dr Theo Luider and Prof. Guido Jenster. After a short postdoctoral training position in Edinburgh, applying metabolomics in the analysis of epigenetics reactions in human cell lines; he joined the Phenome Centre Birmingham team in September 2015 to further implement liquid chromatography and mass spectrometry in the search of novel biomarkers applicable for translation into the clinic.
Rodríguez-Blanco, G. et al. Serum arachidonic acid metabolites are related to prostate cancer progression, The Prostate, 2014, 74, 618-627.
Rodríguez-Blanco, G. et al. Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer. Clin Biochem. 2014, 47, 13-14.
Dr Andrew Chetwynd
Dr Chetwynd has been awarded a BSc in Biochemistry at the University of Surrey and a PhD focussed on the development of nanoflow-nanospray LC-TOF-MS for metabolomic analysis and associated sample preparation with Professor Elizabeth Hill and Dr Alaa Abdul-Sada at the University of Sussex. Following his PhD he remained at Sussex at a post-doctoral researcher to investigate the effect of endocrine disrupting chemicals on the metabolome before moving to Phenome Centre Birmingham in December 2015.
Chetwynd, A.J. et al. Solid phase extraction and nanoflow liquid chromatography-nanoelectrospray ionisation mass spectrometry for improved global urine metabolomics, Analytical Chemistry, 2015, 87, 1158-1165.
Chetwynd, A.J. et al. Use of a pre-analysis osmolality normalisation method to correct for variable urine concentrations and for improved metabolomic analyses, Journal of Chromatography A, 2016, 1431, 103-110
Dr Donna O’Neill
Dr O’Neill was awarded a BSc in Biochemistry in 1999 and started working at the University of Birmingham in 2000. In 2003, she joined the Institute for Cancer Studies working alongside Dr Ashley Martin and Prof Philip Johnson where she was awarded a PhD using proteomic techniques to identify biomarkers for the detection of colorectal cancer. In 2008 Donna moved to the Centre for Endocrinology, Diabetes and Metabolism (CEDAM) in Birmingham where she was involved in the European Network for the Study of Adrenal Tumours (ENSAT), specifically using GC/MS and LC-MS/MS techniques to analyse steroid hormones and their precursors in serum and urine. Donna joined the Phenome Centre Birmingham team in January 2016.
Chortis V, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013 Jan;98(1):161-71.
Krone N, et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab. 2012 Feb;97(2):E257-67.
The bioinformatics team is currently being recruited and will be updated when completed.